<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495260</url>
  </required_header>
  <id_info>
    <org_study_id>XAMNANTIOXAP2010</org_study_id>
    <nct_id>NCT01495260</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants</brief_title>
  <official_title>A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onofre, Aurora Pujol, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Hesperia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Onofre, Aurora Pujol, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      X-linked adrenoleukodystrophy is a rare, demyelinating and neurodegenerative disorder, due to
      a loss of function of a fatty acid transporter, the peroxisomal ABCD1protein. Its more
      frequent phenotype, the adrenomyeloneuropathy in adults, is characterized by axonal
      degeneration in spinal cord, spastic paraparesis and a disabling peripheral neuropathy.
      Actually, there is no efficient treatment for the disease. Our work in the last twelve years
      dissecting the physiopathological basis of the disorder has uncovered an involvement of the
      oxidative stress early in the neurodegenerative cascade. In a preclinical trial we have
      identified an antioxidant cocktail that efficiently reverse the clinical symptoms and the
      axonal degeneration in the mouse model for the disease. We propose the translation of the
      results to an open trial to test the tolerance and effectiveness of these drugs in the
      correction of the previously identified oxidative lesion biomarkers, as a first step to a
      randomized versus placebo, multicentric and international trial. You will be clinically
      explored and assessed in the Hospital Universitari of Bellvitge (HUB) using clinical scales
      for spasticity, disability, electroneurogram and cranial and spinal Nuclear Magnetic
      resonance (NMR). The information will be collected in a data base that will be of great value
      to improve the present attention and the future follow-up to facilitate your inclusion in
      therapeutic randomized, double blind, against placebo clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxidative lesion biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>oxidative lesion biomarkers: protein, DNA and peroxidation biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical parameters</measure>
    <time_frame>2, 6 and 12 months</time_frame>
    <description>spasticity, disability,electroneurograms and evocated potentials. Cranial and spinal NMR will be done at the beginning and the end of the trial.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Adrenomyeloneuropathy</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine, lipoic acid and vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two Dose titration design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine, 800-2400 mg daily for 2 months</description>
    <arm_group_label>N-acetylcysteine, lipoic acid and vitamin E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipoic acid</intervention_name>
    <description>lipoic acid, 300-600 mg daily for 2 months</description>
    <arm_group_label>N-acetylcysteine, lipoic acid and vitamin E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin E</intervention_name>
    <description>vitamin E, 150-300 mg daily for 2 months</description>
    <arm_group_label>N-acetylcysteine, lipoic acid and vitamin E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic AMN patients,

          -  18-64 years old,

          -  male and female,

          -  clinically and biochemically diagnosed;

          -  females must be obligated heterozygotes or must have gene mutation identified.

        Exclusion Criteria:

          -  Pregnant and lactation in females,

          -  advanced cerebral inflammatory disease with cognitive disorder, and/or

          -  need the help of two walking sticks,

          -  epilepsy,

          -  hypersensibility to cysteine related compounds,

          -  transaminases 2 fold up normal values.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de LLobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.neurometabolic-lab.org/</url>
    <description>The Neurometabolic Diseases Lab, led by ICREA Research Professor Aurora Pujol, is integrated in the Neurosciences Area of IDIBELL.</description>
  </link>
  <link>
    <url>http://www.idibell.cat/</url>
  </link>
  <link>
    <url>http://www.bellvitgehospital.cat/</url>
  </link>
  <reference>
    <citation>López-Erauskin J, Fourcade S, Galino J, Ruiz M, Schlüter A, Naudi A, Jove M, Portero-Otin M, Pamplona R, Ferrer I, Pujol A. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol. 2011 Jul;70(1):84-92. doi: 10.1002/ana.22363.</citation>
    <PMID>21786300</PMID>
  </reference>
  <reference>
    <citation>Galino J, Ruiz M, Fourcade S, Schlüter A, López-Erauskin J, Guilera C, Jove M, Naudi A, García-Arumí E, Andreu AL, Starkov AA, Pamplona R, Ferrer I, Portero-Otin M, Pujol A. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid Redox Signal. 2011 Oct 15;15(8):2095-107. doi: 10.1089/ars.2010.3877. Epub 2011 Jun 8.</citation>
    <PMID>21453200</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XALD</keyword>
  <keyword>AMN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

